학술논문
Serum KL-6 levels predict clinical outcomes and are associated with MUC1 polymorphism in Japanese patients with COVID-19
Document Type
article
Author
Takanori Kanai; Yukinori Okada; Yasunori Sato; Katsunori Masaki; Takanori Asakura; Kaori Sakurai; Yuko Kitagawa; Koichi Fukunaga; Hirofumi Kamata; Makoto Ishii; Naoki Hasegawa; Ryuji Koike; Ho Lee; Ryuya Edahiro; Shotaro Chubachi; Kensuke Nakagawara; Ho Namkoong; Hiromu Tanaka; Seiya Imoto; Shuhei Azekawa; Shiro Otake; Takahiro Fukushima; Mayuko Watase; Tatsuya Kusumoto; Akinori Kimura; Satoru Miyano; Seishi Ogawa
Source
BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Subject
Language
English
ISSN
2052-4439
Abstract
Background Krebs von den Lungen-6 (KL-6) is a known biomarker for diagnosis and monitoring of interstitial lung diseases. However, the role of serum KL-6 and the mucin 1 (MUC1) variant (rs4072037) in COVID-19 outcomes remains to be elucidated. We aimed to evaluate the relationships among serum KL-6 levels, critical outcomes and the MUC1 variant in Japanese patients with COVID-19.Methods This is a secondary analysis of a multicentre retrospective study using data from the Japan COVID-19 Task Force collected from February 2020 to November 2021, including 2226 patients with COVID-19 whose serum KL-6 levels were measured. An optimal serum KL-6 level cut-off to predict critical outcomes was determined and used for multivariable logistic regression analysis. Furthermore, the relationship among the allele dosage of the MUC1 variant, calculated from single nucleotide polymorphism typing data of genome-wide association studies using the imputation method, serum KL-6 levels and COVID-19 critical outcomes was evaluated.Results Serum KL-6 levels were significantly higher in patients with COVID-19 with critical outcomes (511±442 U/mL) than those without (279±204 U/mL) (p